We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Probe May Detect Early Cancer

By Biotechdaily staff writers
Posted on 24 Aug 2005
Scientists have discovered a new way to spot subtle chemical changes in the growth of tumors, which may aid the early detection of cancer and other diseases. More...
Their findings were reported in the August 14, 2005, issue of Nature Chemical Biology.

A molecule that can label proteases--protein-chewing enzymes that blast into overdrive in cancerous cells--has been created by Matthew Bogyo, Ph.D., assistant professor of pathology, and colleagues at Stanford University School of Medicine (Palo Alto, CA, USA). The new molecule contains a fluorescent tag that flashes brightly enough to be seen with conventional imaging equipment.

This new activity-based probe is unusual in that it only lights up when the proteases are active. Since it works in living cells, the probe could potentially be used for whole-body imaging for the detection of early warning signs of cancer. Proteases work overtime in tumors that are getting ready to spread, or metastasize, and in angiogenesis. Other cells with hyperactive proteases include cells affected by arthritis, osteoporosis, atherosclerosis, and neurodegenerative disorders such as Alzheimer's.

"This is an important tool for understanding the biochemistry of proteases, and how they play a role in diseases like cancer,” said Dr. Bogyo. "And it's noninvasive and fairly nontoxic, in that it doesn't involve radioisotopes.”

The probe has a number of advantages over other enzyme imaging probes. In one innovation, the scientists added a chemical subunit called a quencher that keeps the probe dark until the protease is activated. The chemical changes activating the enzyme switch the probe on "like a molecular beacon,” noted Dr. Boygo. Since the probe is small enough to pass easily across cell membranes, it can be used inside living cells. The probe also forms a permanent bond with its targeted protease, allowing it to track where the protease is active.

In addition to making new probes, Dr. Bogyo and his team are working on imaging applications. "We have made the tool, now we want to go and use it,” observed Galia Blum, a postdoctoral scholar in Dr. Bogyo's lab and the study's lead author. "Our next step is to generate whole-body images in mice.”





Related Links:
Stanford Medical School

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.